FDA Clears Neptune Medical's Robotic Colonoscopy System Triton 1

TL;DR

• The U.S. Food and Drug Administration has cleared a robotic colonoscopy system called Triton 1, made by a company called Neptune Medical.
• The clearance covers standard colon screenings as well as more complex procedures used to remove growths from the colon, the company says.
• Neptune points to an earlier 50-patient study with strong results, but that study was presented at a conference rather than published in a peer-reviewed journal, and its funding source is not disclosed.
• The clearance means Triton can legally be marketed in the U.S.; it does not by itself prove the system performs better than existing manual colonoscopes.

What happened

The FDA’s own device database shows a clearance dated September 3, 2026, for the Triton 1 System, made by Neptune Medical, Inc. of Burlingame, California. The clearance came through the agency’s 510(k) pathway, under which a device is judged “substantially equivalent” to products already on the market, rather than required to prove new evidence of safety and effectiveness from scratch. The FDA listed it under the category covering flexible and rigid colonoscopes and their accessories.

In its own announcement, republished by BioSpace and Business Wire, Neptune Medical says the clearance covers screening, surveillance and diagnostic colonoscopies, plus two more involved procedures used to remove precancerous growths or early cancers from the lining of the colon: endoscopic mucosal resection and endoscopic submucosal dissection. The company describes Triton’s underlying technology as its own “Dynamic Rigidization” system, which it says is designed to give doctors more consistent control over the scope than they get with a manual endoscope.

“Triton has the potential to fundamentally transform colonoscopy, creating a better experience for both physicians and their patients. Achieving regulatory clearance in the U.S. brings us one step closer to that reality,” said Alex Tilson, Neptune Medical’s founder and CEO. Dr. Jason B. Samarasena, chief of the gastroenterology and hepatology division at the University of California, Irvine, who was an investigator in Neptune’s earlier clinical study of the device, is also quoted in the release: “Triton showed us the possibility of one system that can screen and treat anywhere in the colon, efficiently, thoroughly, and with minimal burden.”

That earlier study, called CARE 1, followed 50 adults who had screening, surveillance or diagnostic colonoscopies with the Triton system at a single medical center in Poland, according to MedTech Dive. Its results were presented at the Digestive Disease Week medical conference in Chicago, not in a peer-reviewed journal. MedTech Dive reports the study found the scope reached the far end of the colon in 100% of cases, with no adverse events, no need to reposition patients or press on their abdomens, and no cases where doctors had to switch to a manual colonoscope. It also reported a 54% rate of detecting adenomas, a type of growth that can turn cancerous, above the 35% rate that MedTech Dive describes as an industry threshold, and a 67% lower average score for physical and mental strain on the endoscopist, measured on a workload scale called NASA-TLX, compared with manual colonoscopy.

Neptune Medical raised $97 million in a 2024 Series D funding round backed by Sonder Capital and by Olympus, a maker of endoscopes. The Robot Report also notes that Neptune launched a subsidiary, Jupiter Endovascular Inc., in 2024.

What this means (and what it does not)

The clearance means Neptune Medical can now legally market and sell the Triton 1 System in the United States for the procedures listed in its FDA filing. It places the company inside a wider push to bring robotic assistance to colonoscopy, a procedure where manual scopes can be difficult to control and unstable positioning is a recognized cause of missed lesions. Olympus, one of Neptune’s own 2024 investors, is separately pursuing GI robotics through a partnership with Revival Healthcare Capital and a distribution deal with EndoRobotics, giving it a stake both in Neptune’s success and in the broader category.

It does not mean the FDA has independently confirmed the strong CARE 1 results, that Triton outperforms manual colonoscopy or competing robotic systems in a head-to-head comparison, or that the device is ready for widespread hospital use. The CEO’s and Dr. Samarasena’s statements praising the system come from Neptune’s own press release, and Samarasena was himself an investigator on the trial that generated the company’s central evidence.

What we still do not know

No source discloses who funded the CARE 1 study or confirms it was run independently of Neptune Medical, and its results have not appeared in a peer-reviewed journal — only at a conference and in the company’s own materials. The study also enrolled just 50 patients at one site in Poland, and no source addresses whether those results would hold up in larger or U.S. populations. The FDA’s database entry confirms the “substantially equivalent” finding but does not say which predicate device it was compared against or what mix of bench, animal or clinical data supported the submission. No source states when Triton 1 will actually reach U.S. hospitals, at what price, or how insurers would cover it, and none provides direct comparative data against existing manual endoscopes or rival robotic systems from Olympus, Revival Healthcare Capital/EndoRobotics or others. It is also unclear whether Neptune’s earlier 510(k) clearances, such as for its Pathfinder Endoscope Overtube line, are related accessories or a separate product family.